| Outcome Measures: |
Primary: safety and tolerability of DS-7309, number, type and severity of adverse events, 23 days, Day -7 through Day 16|determine the pharmacokinetics of DS-7309 after repeated doses, Cmax, Tmax, area under the concentration curve (AUC), 23 days, Day-7 through Day 16|determine glycemic response, glycemic response will be assessed by blood sampling for plasma glucose after a meal tolerance test and from 24h weighted mean glucose on Day -1 and Day 12, 23 days, Day -7 through Day 16 | Secondary: To assess the effects of repeated doses of DS-7309 on plasma insulin levels in T2DM subjects, To assess the effects of repeated doses of DS-7309 on plasma insulin levels in T2DM subjects, 23 days, Day -7 through Day 16|To assess the effects of repeated doses of DS-7309 on blood pressure, To assess the effects of repeated doses of DS-7309 on blood pressure (by means of 24 h ambulatory blood pressure measurements (ABPMs), 23 days, Day -7 through Day 16|To assess the effects of repeated doses of DS-7309 on lipid profile, To assess the effects of repeated doses of DS-7309 on lipid profile (total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol and triglycerides), 23 days, Day -7 through Day 16|To assess the effects of repeated doses of DS-7309 on plasma lactate levels, To assess the effects of repeated doses of DS-7309 on plasma lactate levels, 23 days; Day -7 through Day 16|To assess the effects of repeated doses of DS-7309 on C-peptide levels in T2DM subjects, To assess the effects of repeated doses of DS-7309 on C-peptide levels in T2DM subjects, 23 days, Day -7 through Day 16|To assess the effects of repeated doses of DS-7309 on glucagon levels in T2DM subjects, To assess the effects of repeated doses of DS-7309 on glucagon levels in T2DM subjects, 23 days, Day -7 through Day 16
|
